Our highly specialised technologies (HST) programme is designed specifically to evaluate technologies for ultra-rare, debilitating conditions. It helps encourage research and innovation in areas where ...

As set out in the NHS Commercial Framework for New Medicines, a commercial access agreement (CAA) is a complex confidential agreement and is agreed at NHS England’s discretion. A CAA proposal can only ...